Biblio Discovery — Demo Discovery Service

15 results for "Igor Stukalin"

Showing 1–15 · 0.38 seconds · RSS

  1. Journal Article

    Contemporary treatment of metastatic renal cell carcinoma

    Igor Stukalin; Nimira Alimohamed; Daniel Y.C. Heng

    Oncology Reviews, Vol. 10 No. 1 · 2016 · English · DOAJ Scopus

    The introduction of targeted therapy has revolutionized the treatment of patients with metastatic renal cell carcinoma (mRCC). The current standard of care focuses on the inhibition of angiogenesis through the targeting of the vascular endothelial growth factor receptor (VEGFR) and the mammalian…

  2. Journal Article

    Primary adenocarcinoma of bulbomembranous urethra: An exceedingly rare carcinoma in a male patient

    Igor Stukalin; Yuan Gao; Shelley Spaner et al.

    Urology Case Reports, Vol. 26 · 2019 · English · DOAJ Scopus

    Primary urethral carcinomas are rare tumors and their incidence increases with age. Urothelial carcinoma is the most common histologic type of primary urethral carcinoma, followed by squamous cell carcinoma and adenocarcinoma. Adenocarcinoma arising in the male urethra is an exceedingly rare…

  3. Journal Article Full text

    Brief Report: Trends in Incidence, Mortality, and Disability-Adjusted Life Years for Early-Onset Colorectal Cancer in Canada Between 1990 and 2019

    Igor Stukalin; Mehul Gupta; Katherine Buhler et al.

    Current Oncology, Vol. 31 No. 12 · 2024 · English · DOAJ Scopus

    Background: Colorectal cancer is the third most common malignancy globally. Early-onset colorectal cancer (EOCRC) is becoming a growing healthcare focus globally, particularly in North America. We estimated trends in incidence, mortality, and disability-adjusted life years (DALYs) for EOCRC in…

  4. Journal Article

    Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: a retrospective observational cohort study

    Mehul Gupta; Igor Stukalin; Daniel E. Meyers et al.

    Frontiers in Oncology, Vol. 14 · 2024 · English · DOAJ Scopus

    BackgroundThe association between objective imaging response and first line immune checkpoint inhibitor (ICI) therapy regimes in advanced melanoma remains uncharacterized in routine practice.MethodsWe conducted a multi-center retrospective cohort analysis of advanced melanoma patients receiving…

  5. Journal Article Full text

    Durvalumab-Associated Pneumonitis in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Real-World Population Study

    Chloe Ahryung Lim; Sunita Ghosh; Hali Morrison et al.

    Current Oncology, Vol. 30 No. 12 · 2023 · English · DOAJ Scopus

    The PACIFIC trial led to a new standard of care for patients with locally advanced lung cancer, but real-world practice has demonstrated that immune checkpoint inhibitor (ICI) pneumonitis can lead to significant clinical complications. This study aimed to examine the clinical predictors, outcomes…

  6. Journal Article Full text

    Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab

    Siddhartha Goutam; Igor Stukalin; Benjamin Ewanchuk et al.

    Current Oncology, Vol. 29 No. 10 · 2022 · English · DOAJ Scopus

    Immune checkpoint inhibitors (ICIs) for treatment of metastatic melanoma (MM) offer lasting overall survival (OS) benefit in a subset of patients. However, outcomes remain poor for non-responders. Clinical predictors of long-term survival remain elusive. We utilized the Alberta Immunotherapy…

  7. Journal Article Full text

    Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma

    Taylor E. Woo; Igor Stukalin; Philip Q. Ding et al.

    Current Oncology, Vol. 30 No. 10 · 2023 · English · DOAJ Scopus

    Background: The majority of melanoma is diagnosed in individuals between 55 and 84 years old. Current data varied in reporting differences in survival outcomes amongst different age groups. Methods: A retrospective, multi-center, provincial cohort database was used to investigate the relationship…

  8. Journal Article

    Effectiveness of immune checkpoint inhibitor therapy on bone metastases in non-small-cell lung cancer

    Annalise G. Abbott; Daniel E. Meyers; Golpira Elmi-Assadzadeh et al.

    Frontiers in Immunology, Vol. 15 · 2024 · English · DOAJ Scopus

    BackgroundBone metastases (BoMs) are prevalent in patients with metastatic non-small-cell lung cancer (NSCLC) however, there are limited data detailing how BoMs respond to immune checkpoint inhibitors (ICIs). The purpose of this study was to compare the imaging response to ICIs of BoMs against…

  9. Journal Article

    Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors

    Michael S. Sander; Igor Stukalin; Isabelle A. Vallerand et al.

    Cancer Medicine, Vol. 10 No. 8 · 2021 · English · DOAJ Scopus

    Abstract Background Metastatic uveal melanoma (MUM) is associated with poor survival and inferior response to immune checkpoint inhibitor (ICI) therapy when compared with metastatic cutaneous melanoma. Currently, prognostic biomarkers are lacking to guide treatment decisions. Patients and Methods…

  10. Journal Article

    Associations Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Cancer Risk: A Systematic Review and Meta-Analysis

    Isha Lalani BSc; Reynaldo Nambayan BSc; Chantelle Carbonell BHSc et al.

    Cancer Control, Vol. 33 · 2026 · English · DOAJ Scopus

    Introduction Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for control of type 2 diabetes and cardiovascular disease (CVD) risk reduction is increasing. Given the established link between obesity and multiple cancers, there is growing interest in the potential effects of GLP-1RAs on…

  11. Journal Article Full text

    The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer

    Domen Ribnikar; Igor Stukalin; Philippe L. Bedard et al.

    Current Oncology, Vol. 28 No. 1 · 2020 · English · DOAJ Scopus

    We investigated the prognostic utility of pre-chemotherapy neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic germ cell tumors (GCTs) undergoing first-line chemotherapy. We utilized two institutional databases to analyze the pretreatment-derived NLR (dNLR). Predictive accuracy was…

  12. Journal Article Full text

    Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database

    Heidi A. I. Grosjean; Samantha Dolter; Daniel E. Meyers et al.

    Current Oncology, Vol. 28 No. 5 · 2021 · English · DOAJ Scopus

    The emergence of immunotherapy revolutionized the treatment of non-small-cell-lung cancer (NSCLC), with multiple landmark clinical trials establishing the efficacy of these agents. However, many patients who receive immunotherapy in clinical practice would be considered clinical trial ineligible…

  13. Journal Article

    Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors

    Daniel E. Meyers, MD, MSc; Meghann Pasternak, MD, MSc; Samantha Dolter, MD et al.

    JTO Clinical and Research Reports, Vol. 4 No. 4 · 2023 · English · DOAJ Scopus

    Introduction: Landmark trials testing immune checkpoint inhibitors (ICIs) in advanced NSCLC are difficult to extrapolate to real-world practice given the exclusion of patients with poor (i.e., ≥2) Eastern Cooperative Oncology Group performance status (ECOG PS). We sought to evaluate the impact of…

  14. Journal Article

    Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)

    Igor Stukalin; J. Connor Wells; Anna Fraccon et al.

    Kidney Cancer, Vol. 2 · 2018 · English · DOAJ Scopus

    Background: Fourth-line therapy (4LT) in the treatment of metastatic renal cell carcinoma (mRCC) varies significantly due to the lack of data and recommendations to guide treatment decisions. Objective: To evaluate the use and efficacy of 4LT in mRCC patients. Methods: The International mRCC…

  15. Journal Article

    Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study

    Nicholas Jones; Tarek Haykal; Noha Abdel-Wahab et al.

    Journal for ImmunoTherapy of Cancer, Vol. 13 No. 3 · 2025 · English · DOAJ Scopus

    Background Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited.Methods This is an international multicenter retrospective study of patients with cancer and cardiac metastasis at baseline…